Close
Almac
Achema middle east

Velesco Pharma set for clinical manufacturing capacity expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
- Advertisement -

Pharmaceutical development and clinical manufacturing expert, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharma’s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.

As part of the expansion, the company has continued to  invest in its growing team  with the recent promotion of two senior leaders. Peter Angus has moved into the role of Vice President of Research while Lisa Crandall is now Vice President of Development. Both have been with Velesco Pharma since its inception.

Founded in 2007, Velesco Pharma supports early and later stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.

Dave Barnes, Velesco Pharma’s CEO: “This investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects.

“Our team forged their careers in big pharma R&D and bring a wealth of expertise to the table. This experience combined with our personalized and agile approach makes us an ideal choice for clients in the critical early and later stage drug development phases.

“As a business we have always placed great emphasis on adding scientific value to the drug development process and this continues to be central to our ethos as we expand and move forward.”

The new facility is set to be fully operational by the end of this year.

For more information on Velesco Pharma visit  http://www.velescopharma.com

About Velesco Pharmaceutical Services

Velesco Pharma was formed by former big pharma R&D colleagues and focuses on supporting early and later stage drug development. Velesco provides fast and cost-effective contract analytical development and drug formulation services along with cGMP clinical supplies offering a full range of non-sterile dosage forms. The team offers personalized project management, state-of-the-art facilities and an experienced laboratory staff leading to comprehensive research relationships.

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »